Phenotypical expression of CYP2D6 in Amerindians of Tepehuano origin from Durango, Mexico

Proceedings of the Western Pharmacology Society

Volumn 48, Issue , 2005, Pages 102-107

  Lares Asseff, Ismael ^a,c   Sosa Macías, Martha ^a   Elizondo Azuela, Guillermo ^b   Flores Pérez, Carmen ^c   Flores Pérez, Janett ^c   Bradley Alvarez, Francisco ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN;

ADULT; AGE; AMERICAN INDIAN; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENDER; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; NUTRITIONAL STATUS; PHENOTYPE; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; MALE; MEXICO; MIDDLE AGED; NUTRITIONAL STATUS; PHENOTYPE; SEX FACTORS;

EID: 30144443137     PISSN: 00838969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Kallow, W. (1991) Trends Pharmacol. Sci. 12(3), 102-107.
2. Bertilsson, L. (1995) Clin. Pharmacokinet. 29, 192-209.
3. Guengerich, F.P. (1995) Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450, Plenum Press, New York.
4. Gonzalez, F.J. and Meyer, U.A. (1991) Molecular genetics of the debrisoquin-sparteine polymorphism. Clin. Pharmacol. Ther. 50, 233-238.
5. Daly, A.K., Brockmöller, J., Broly, F., Eichelbaum, M., Evans, W.E., Gonzalez, F.J., et al. (1996) Pharmacogenetics 6, 193-201.
6. Brøsen, K. and Gram, L.F. (1989) Eur. J. Clin. Pharmacol. 36, 537-547.
7. Sjöqvist, F. and Bertilsson, L. (1986) Slow hydroxylation of tricyclic antidepressants-relationship to polymorphic drug oxidation. In: Kalow, W., Goedde, H.W., Agarwal, D.P., editors. Ethnic differences in reactions to drugs and xenobiotics. Alan R Liss, New York.
8. Eichelbaum, M. and Gross, A.S. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol. Ther. 46, 377-394.
9. Kohler, D., Hartter, S., Fuchs, K., et al. (1997) Pharmacogenetics 7, 453-461.
10. Dayer, P., Leemann, T. and Striberni, R. (1989) Clin. Pharmacol. Ther. 45, 34-40.
11. Jacqz-Aigrain, E., Funck-Brentano, C. and Cresteil, T. (1993) Pharmacogenetics 3, 197-204.
12. Alván, G., Bechtel, P., Iselius, L. and Gundert-Remy, U. (1990) Eur. J. Clin. Pharmacol. 39, 533-537.
13. Jones, D.R., Gorski, J.C., Haehner, B.D., O'Mara, E.M. Jr. and Hall, S.D. (1996) Clin. Pharmacol. Ther. 60, 374-384.
14. Sonne, J. (1996) Ther. Drug Monit. 18, 397-401.
15. Kall, M.A., Vang, O. and Clausen, J. (1996) Carcinogenesis 17(4), 793-799.
16. Vainer, J.L. and Chouinard, G. (1994) J. Clin. Psychopharmacol. 14, 284-285.
17. Carrillo, J.A., Jerling, M. and Bertilsson, L. (1995) J. Clin. Psychopharmacol. 15, 376-377.
18. Krishnaswamy, K. (1987) Effects of malnutrition on drug metabolism and toxicity in humans. In: Hathcock, J.N., editor. Nutritional Toxicology Vol 2. Academic Press, Inc, Orlando (FL).
19. Lares-Asseff, I., Cravioto, J., Santiago, P., et al. (1992) Clin. Pharmacol. Ther. 51, 42-50.
20. Arias, T.D., Jorge, L.F., Lee, D., Barrantes, R. and Inaba, T. (1988) Clin. Pharmacol. Ther. 43, 456-465.
21. Arias, T.D., Inaba, T., Cooke, R.G. and Jorge, L.F. (1988) Clin. Pharmacol. Ther. 44, 343-352.
22. Jorge, L.F., Eichelbaum, M., Griese, E.U., Inaba, T. and Arias, T.D. (1999) Pharmacogenetics 9, 217-228.
23. Mendoza, R., Yvonne, Wan, Y.J., Poland, R.E., Smith, M., Zheng, Y., Berman, N. and Lin, K.N. (2001) Clin. Pharmacol. Ther. 70(6), 552-560.
24. Yoa-Pu Hu, O., Hung-Shang, T., Hsien-Yuan, L., Wen-Ho, Ch. and Teh-Min, H. (1998) Pharmacol. Exp. Ther. 285, 955-960.
25. Castilla Serna, L. and Cravioto, J. (1991) Estadistica Simplificada para la Investigación en Ciencias de la Salud. Editorial Trillas, México, D.F.
26. SPSS for Windows. Release 10.0.1 (27 Oct 1999) Standar Version.
27. Tennezé, L., Verstuyft, C., Becquemont, L., Poirier, J.M., Wilkinson, G.R. and Funck-Brentano, C. (1999) Clin. Pharmacol. Ther. 66, 582-588.
28. Smith, D.A., Abel, S.M., Hyland, R. and Jones, B.C. (1998) Xenobiotica 28, 1095-1128.
29. Otton, S.V., Wu, D., Joffe, R.T., Cheung, S.W. and Sellers, E.M. (1993) Clin. Pharmacol. Ther. 53, 401-409.
30. Chládek, J., Zimová, G., Beránek, M. and Martínková, J. (2000) Eur. J. Clin. Pharmacol. 56, 651-657.
31. Marez, D., Legrand, M., Sabbagh, N., Lo Guidice, J.M., Spire, C., Lafitte, J.J., Meyer, U.A. and Broly, F. (1997) Pharmacogenetics 7, 193-202.
32. Griese, E.U., Zanger, U.M., Brudermanns, U., Gaedigk, A., Mikus, G., Mörike, K., Stüven, T. and Eichelbaum, M. (1998) Pharmacogenetics 8, 15-26.
33. Wang, S.L., Lai, M.D., Lai, M.L. and Huang, J.D. (1995) Pharmacogenetics 5, 385-388.
34. Steiner, E., Iselius, L., Alván, G., Lindsten, J. and Sjöqvist, F. (1985) Clin. Pharmacol. Ther. 38, 394-401.
35. Bock, K.W., Schrenk, D., Forster, A., et al. (1994) Pharma 4, 209-218.
36. Mahgoub, A., Idle, J.R., Dring, L.G., Lancaster, R. and Smith, R.L. (1977) Lancet 2, 584-586.
37. McCune, J.S., Lindley, C., Decker, J.L., Williamson, K.M., Meadowcroft, A.M., Graft, D., Sawyer, W.T., Blough, D.K. and Pieper, J.A. (2001) J. Clin. Pharmacol. 41, 723-731.
38. Woodworth, J.R., Dennis, S.R., Moore, L. et al. (1987) J. Clin. Pharmacol. 27, 139-143.
39. Walker, F.O. and Hunt, V.P. (1989) Clin. Neuropharmacol. 12, 322-330.
40. Ellenhorn, M.J. and Barceloux, D.G. (1988) Medical Toxicology: diagnosis and treatment of human poisoning, Elsevier, New York.